Log in

NASDAQ:MEDP - Medpace Stock Price, Forecast & News

$99.58
-0.34 (-0.34 %)
(As of 02/23/2020 10:06 AM ET)
Today's Range
$98.25
Now: $99.58
$100.40
50-Day Range
$82.53
MA: $90.43
$100.30
52-Week Range
$50.14
Now: $99.58
$101.12
Volume140,147 shs
Average Volume175,839 shs
Market Capitalization$3.59 billion
P/E Ratio40.15
Dividend YieldN/A
Beta1.5
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEDP
CUSIPN/A
Phone513-579-9911

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$704.59 million
Cash Flow$3.56 per share
Book Value$16.56 per share

Profitability

Net Income$73.18 million

Miscellaneous

Employees2,900
Market Cap$3.59 billion
Next Earnings Date2/24/2020 (Confirmed)
OptionableOptionable

Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.


Medpace (NASDAQ:MEDP) Frequently Asked Questions

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

How were Medpace's earnings last quarter?

Medpace Holdings Inc (NASDAQ:MEDP) announced its quarterly earnings results on Tuesday, October, 29th. The company reported $0.71 earnings per share for the quarter, hitting the consensus estimate of $0.71. The company had revenue of $216.20 million for the quarter, compared to the consensus estimate of $217.14 million. Medpace had a return on equity of 17.06% and a net margin of 11.35%. The firm's revenue for the quarter was up 20.6% compared to the same quarter last year. During the same period last year, the firm earned $0.67 EPS. View Medpace's Earnings History.

When is Medpace's next earnings date?

Medpace is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Medpace.

How can I listen to Medpace's earnings call?

Medpace will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for MEDP?

4 equities research analysts have issued 12-month target prices for Medpace's shares. Their forecasts range from $62.00 to $87.00. On average, they expect Medpace's stock price to reach $75.33 in the next year. This suggests that the stock has a possible downside of 24.3%. View Analyst Price Targets for Medpace.

What is the consensus analysts' recommendation for Medpace?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.

Has Medpace been receiving favorable news coverage?

News articles about MEDP stock have trended very negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medpace earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future. View News Stories for Medpace.

Who are some of Medpace's key competitors?

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Alibaba Group (BABA), Adobe (ADBE), Baidu (BIDU), Paycom Software (PAYC), Veeva Systems (VEEV), Fortinet (FTNT), Roku (ROKU) and Arista Networks (ANET).

Who are Medpace's key executives?

Medpace's management team includes the folowing people:
  • Dr. August James Troendle, Chairman, Pres & CEO (Age 63)
  • Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)
  • Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)
  • Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Todd Meyers, VP of Bus. Devel. & Marketing

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are Medpace's major shareholders?

Medpace's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Pendal Group Ltd (3.55%), State Street Corp (2.21%), Renaissance Technologies LLC (1.63%), Acadian Asset Management LLC (1.47%), Geode Capital Management LLC (1.19%) and Goldman Sachs Group Inc. (1.11%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Institutional Ownership Trends for Medpace.

Which institutional investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., PNC Financial Services Group Inc., Marshall Wace LLP, Goldman Sachs Group Inc., AQR Capital Management LLC, SG Americas Securities LLC and Bowling Portfolio Management LLC. Company insiders that have sold Medpace company stock in the last year include Jesse J Geiger and Stephen P Ewald. View Insider Buying and Selling for Medpace.

Which institutional investors are buying Medpace stock?

MEDP stock was acquired by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd, Man Group plc, Renaissance Technologies LLC, California Public Employees Retirement System, Bank of Montreal Can, Great West Life Assurance Co. Can and McGuire Investment Group LLC. View Insider Buying and Selling for Medpace.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $99.58.

How big of a company is Medpace?

Medpace has a market capitalization of $3.59 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,900 workers across the globe.View Additional Information About Medpace.

What is Medpace's official website?

The official website for Medpace is http://www.medpace.com/.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]


MarketBeat Community Rating for Medpace (NASDAQ MEDP)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  279 (Thanks for Voting!)
Underperform Votes:  286 (Thanks for Voting!)
Total Votes:  565
MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Featured Article: Gap Down Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel